Read by QxMD icon Read

High grade non muscle invasive bladder cancer

Margarida Ferreira-Teixeira, Daniela Paiva-Oliveira, Belmiro Parada, Vera Alves, Vitor Sousa, Obinna Chijioke, Christian Münz, Flávio Reis, Paulo Rodrigues-Santos, Célia Gomes
BACKGROUND: High-grade non-muscle invasive bladder cancer (NMIBC) has a high risk of recurrence and progression to muscle-invasive forms, which seems to be largely related to the presence of tumorigenic stem-like cell populations that are refractory to conventional therapies. Here, we evaluated the therapeutic potential of Natural Killer (NK) cell-based adoptive immunotherapy against chemoresistant bladder cancer stem-like cells (CSCs) in a pre-clinical relevant model, using NK cells from healthy donors and NMIBC patients...
October 21, 2016: BMC Medicine
Hao Min Li, Baihetiya Azhati, Mulati Rexiati, Wen Guang Wang, Xiao Dong Li, Qiang Liu, Yu-Jie Wang
OBJECTIVE: To investigate the effect of smoking status, cumulative smoking exposure and smoking cessation on the outcomes of patient with non-muscle-invasive bladder cancer (NMIBC). METHODS: We collected smoking data from 484 patients with NMIBC who were treated with transurethral resection (TUR); smoking status was categorized as (never smokers vs current smokers vs former smokers). Cumulative smoking exposure was categorized as high smoking exposure (cigarette index ≥400) versus low smoking exposure (cigarette index <400)...
October 20, 2016: International Urology and Nephrology
Naoto Kamiya, Hiroyoshi Suzuki, Takahito Suyama, Masayuki Kobayashi, Satoshi Fukasawa, Nobuyuki Sekita, Kazuo Mikami, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa
BACKGROUND: A retrospective, multi-institutional collaborative study was conducted to evaluate the impact of second transurethral resection (TUR) on the clinical outcome of non-muscle invasive high-grade bladder cancer and to identify predictors of invasion to the lamina propria (pT1) or deeper and residual tumor at the second TUR. METHODS: The clinical and pathological features of 198 patients with non-muscle invasive high-grade bladder cancer treated in five medical institutions from April 1990 to March 2013 were reviewed retrospectively...
October 15, 2016: International Journal of Clinical Oncology
Steve Goodison, Osamu Ogawa, Yoshiyuki Matsui, Takashi Kobayashi, Makito Miyake, Sayuri Ohnishi, Kiyohide Fujimoto, Yunfeng Dai, Yoshiko Shimizu, Kazue Tsukikawa, Hideki Furuya, Charles J Rosser
BACKGROUND: Bladder cancer (BCa) is among the most commonly diagnosed malignancies worldwide, and due the high rate of post-operative disease recurrence, it is one of the most prevalent in many countries. The development of non-invasive molecular assays that can accurately detect and monitor BCa would be a major advance, benefiting both patients and healthcare systems. We have previously identified a urinary protein biomarker panel that is being developed for application in at-risk patient cohorts...
October 7, 2016: Journal of Translational Medicine
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Tomonori Habuchi
OBJECTIVE: Intravesical BCG therapy is widely used for the treatment of high-risk, non-muscle-invasive bladder cancer. Among various reported side-effects, decreased bladder capacity is a serious side-effect that significantly worsens patients' quality of life. This article reports the efficacy and safety of bladder hydrodistension (BHD) in six patients with seriously decreased bladder capacity caused by BCG treatment. METHODS: Six patients with low bladder capacity (<100 ml in voiding diaries) and complaint of grade 3 irritative symptoms were diagnosed with decreased bladder capacity and treated with BHD...
October 5, 2016: Scandinavian Journal of Urology
Bin B Dong, Jia S Yan, Yang Y Yan, Tian C Xie, Liang Xu, Guang H Hu, Yun F Xu, Min Liu
BACKGROUND: Pigment epithelium-derived factor (PEDF) has been reported to inhibit angiogenesis in bladder cancer, but whether it modulates epithelial-mesenchymal transition (EMT) remains unknown. METHODS: We have included 68 samples of non-muscle invasive bladder cancer in this study. Immunohistochemistry was performed in all sample sections for expressions of PEDF, SNAI2, Vimentin and E-cadherin, which were quantified and The EMT index (EMTi) was calculated by Vimentin/E-cadherin...
September 20, 2016: Panminerva Medica
J Alfred Witjes, Guido Dalbagni, Robert J Karnes, Shahrokh Shariat, Steven Joniau, Joan Palou, Vincenzo Serretta, Stéphane Larré, Savino di Stasi, Renzo Colombo, Marek Babjuk, Per-Uno Malmström, Nuria Malats, Jacques Irani, Jack Baniel, Tommaso Cai, Eugene Cha, Peter Ardelt, John Varkarakis, Riccardo Bartoletti, Martin Spahn, Francesca Pisano, Paolo Gontero, Richard Sylvester
BACKGROUND: Potential differences in efficacy of different bacillus Calmette-Guérin (BCG) strains are of importance for daily practice, especially in the era of BCG shortage. OBJECTIVE: To retrospectively compare the outcome with BCG Connaught and BCG TICE in a large study cohort of pT1 high-grade non-muscle-invasive bladder cancer patients. DESIGN, SETTING, AND PARTICIPANTS: Individual patient data were collected for 2,451 patients with primary T1G3 tumors from 23 centers who were treated with BCG for the first time between 1990 and 2011...
September 14, 2016: Urologic Oncology
Niccolo Passoni, Bishoy Gayed, Payal Kapur, Arthur I Sagalowsky, Shahrokh F Shariat, Yair Lotan
PURPOSE: To assess if a panel of cell-cycle markers could improve the discrimination of European Organization for Research and Treatment of Cancer (EORTC) and Spanish Urological Club for Oncological Treatment (CUETO) models in predicting recurrence and progression of high-grade non-muscle-invasive bladder cancer (NMIBC). MATERIALS AND METHODS: Between January 2007 and January 2012, every patient with high-grade NMIBC treated with transurethral resection of bladder underwent immunohistochemical staining for 5 biomarkers (p21, p27, p53, KI-67, and cyclin E1)...
September 13, 2016: Urologic Oncology
Rossana Critelli, Francesca Fasanelli, Marco Oderda, Silvia Polidoro, Manuela Bianca Assumma, Clara Viberti, Mirko Preto, Paolo Gontero, Giuseppina Cucchiarale, Irene Lurkin, Ellen C Zwarthoff, Paolo Vineis, Carlotta Sacerdote, Giuseppe Matullo, Alessio Naccarati
Most bladder cancer (BC) patients need life-long, invasive and expensive monitoring and treatment, making it a serious burden on the health system. Thus, there is a pressing need for an accurate test to assist diagnosis and surveillance of BC as an alternative to cystoscopy. Mutations in human TERT, FGFR3, PIK3CA, and RAS genes have been proposed as potential molecular markers in bladder tumor. Their concomitant presence in urine samples has not been fully explored.We investigated a panel of mutations in DNA from exfoliated urinary cells of 255 BC patients at diagnosis...
September 7, 2016: Oncotarget
Keita Kobayashi, Hiroaki Matsumoto, Hideyasu Matsuyama, Nakanori Fujii, Ryo Inoue, Yoshiaki Yamamoto, Kazuhiro Nagao
CD44, a major surface receptor for hyaluronic acid, has multiple isoforms and represents a major cancer stem cell marker for various epithelial tumors. CD44 variant 9 (CD44v9) was correlated with recurrence and metastasis in gastric and colon cancer. We examined its role in invasion and as a biomarker for the basal muscle invasive molecular subtype showing worse prognosis, and for tumor progression in high risk (pT1/high grade) non‑muscle invasive bladder cancers (NMIBCs). CD44v9, cytokeratin 5/6 (CK5/6), and cytokeratin 20 (CK20) expression was evaluated by immunohistochemistry in 98 pathologically confirmed specimens (36 muscle and 62 high‑risk non‑muscle) and correlated to clinical outcome...
September 1, 2016: Oncology Reports
Feng Chen, Tao Huang, Yu Ren, Junjun Wei, Zhongguan Lou, Xue Wang, Xiaoxiao Fan, Yirun Chen, Guobin Weng, Xuping Yao
BACKGROUND: Methylation of the tumor suppressor gene H-cadherin (CDH13) has been reported in many cancers. However, the clinical effect of the CDH13 methylation status of patients with bladder cancer remains to be clarified. METHODS: A systematic literature search was performed to identify eligible studies in the PubMed, Embase, EBSCO, CKNI and Wanfang databases. The pooled odds ratio (OR) and the corresponding 95 % confidence interval (95 % CI) was calculated and summarized...
2016: BMC Urology
Michelle R Downes, Berber Weening, Bas W G van Rhijn, Cherry L Have, Kilian M Treurniet, Theodorus H van der Kwast
AIMS: The dual pathway model of urothelial carcinogenesis does not fully explain grade and stage progression in patients with initial low grade, non-muscle invasive urothelial carcinomas. FGFR3 mutations are a hallmark of the low grade pathway, with subsequent progression to muscle invasion occurring when FGFR3 mutant tumours exhibit a homozygous CDKN2A deletion. We hypothesized that grade heterogeneity represents the morphologic manifestation of molecular changes associated with disease progression...
August 17, 2016: Histopathology
Gilberto L Almeida, Wilson F S Busato, Carmen Marcondes Ribas, Jurandir Marcondes Ribas, Ottavio De Cobelli
: Validate the EORTC risk tables in Brazilian patients with NMIBC. METHODS: 205 patients were analyzed. The 6 parameters analyzed were: histologic grading, pathologic stage, size and number of tumors, previous recurrence rate and concomitant CIS. The time for first recurrence (TFR), risk score and probability of re¬currence were calculated and compared to the probabilities obtained from EORTC risk tables. C-index was calculated and accuracy of EORTC tables was analyzed...
August 10, 2016: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Rajan Veeratterapillay, Rakesh Heer, Mark I Johnson, Raj Persad, Christian Bach
Bladder cancer is the second commonest urinary tract malignancy with 70-80 % being non-muscle invasive (NMIBC) at diagnosis. Patients with high-risk NMIBC (T1/Tis, with high grade/G3, or CIS) represent a challenging group as they are at greater risk of recurrence and progression. Intravesical Bacilli Calmette-Guerin (BCG) is commonly used as first line therapy in this patient group but there is a current worldwide shortage. BCG has been shown to reduce recurrence in high-risk NMIBC and is more effective that other intravesical agents including mitomycin C, epirubicin, interferon-alpha and gemcitabine...
September 2016: Current Urology Reports
Thomas Seisen, Benoit Peyronnet, Jose Luis Dominguez-Escrig, Harman M Bruins, Cathy Yuhong Yuan, Marko Babjuk, Andreas Böhle, Maximilian Burger, Eva M Compérat, Nigel C Cowan, Eero Kaasinen, Joan Palou, Bas W G van Rhijn, Richard J Sylvester, Richard Zigeuner, Shahrokh F Shariat, Morgan Rouprêt
CONTEXT: There is uncertainty regarding the oncologic effectiveness of kidney-sparing surgery (KSS) compared with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC). OBJECTIVE: To systematically review the current literature comparing oncologic outcomes of KSS versus RNU for UTUC. EVIDENCE ACQUISITION: A computerised bibliographic search of the Medline, Embase, and Cochrane databases was performed for all studies reporting comparative oncologic outcomes of KSS versus RNU...
July 28, 2016: European Urology
Robert Iliev, Renata Kleinova, Jaroslav Juracek, Jan Dolezel, Zuzana Ozanova, Michal Fedorko, Dalibor Pacik, Marek Svoboda, Michal Stanik, Ondrej Slaby
Long non-coding RNA TUG1 is involved in the development and progression of a variety of tumors. Little is known about TUG1 function in high-grade muscle-invasive bladder cancer (MIBC). The aims of our study were to determine expression levels of long non-coding RNA TUG1 in tumor tissue, to evaluate its relationship with clinico-pathological features of high-grade MIBC, and to describe its function in MIBC cells in vitro. TUG1 expression levels were determined in paired tumor and adjacent non-tumor bladder tissues of 47 patients with high-grade MIBC using real-time PCR...
July 27, 2016: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
Takashi Kawahara, Satoshi Inoue, Hiroki Ide, Eiji Kashiwagi, Shinji Ohtake, Taichi Mizushima, Peng Li, Yi Li, Yichun Zheng, Hiroji Uemura, George J Netto, Hitoshi Ishiguro, Hiroshi Miyamoto
The expression status of ZKSCAN3, a zinc-finger transcription factor containing KRAB and SCAN domains, as well as its biological significance, in human bladder cancer remains largely unknown. In the current study, we aimed to determine the functional role of ZKSCAN3 in bladder cancer progression. Immunohistochemistry in tissue specimens detected ZKSCAN3 signals in 138 (93.2%) of 148 urothelial neoplasms, which was significantly higher than in non-neoplastic urothelial tissues [76 (84.4%) of 90; P=0.044]. Correspondingly, the levels of ZKSCAN3 gene were significantly elevated in bladder tumors, compared with those in adjacent normal-appearing bladder mucosae (P=0...
July 18, 2016: Oncotarget
Andrew T Lenis, Nicholas M Donin, Mark S Litwin, Christopher S Saigal, Julie Lai, Jan M Hanley, Badrinath R Konety, Karim Chamie
BACKGROUND: Bacillus Calmette-Guérin (BCG) is the reference standard treatment for patients with high-grade, non-muscle-invasive bladder cancer (NMIBC). We previously described noncompliance with guidelines for BCG use in patients with high-risk disease. In the current study, we sought to characterize how the number of endoscopic resections of bladder tumors affects BCG utilization using population-level data. PATIENTS AND METHODS: We queried a Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database to evaluate claims records of 4776 patients diagnosed with high-grade NMIBC between 1992 and 2002 and followed until 2007, who survived for at least 2 years and who did not undergo definitive treatment with cystectomy, radiotherapy, or systemic chemotherapy...
June 25, 2016: Clinical Genitourinary Cancer
Romain Mathieu, Ilaria Lucca, Morgan Rouprêt, Alberto Briganti, Shahrokh F Shariat
Outcome prediction in patients with bladder cancer has improved through the development of nomograms and predictive models. However, integration of further characteristics such as lymphovascular invasion (LVI) might increase the accuracy and clinical utility of these instruments. Assessment and reporting of LVI in specimens from transurethral resection of the bladder tumour (TURBT) or biopsy in patients with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) might enable improved staging, prognostication and clinical decision-making...
August 2016: Nature Reviews. Urology
Shenghua Liu, Limin Zhang, Lujia Zou, Hui Wen, Qiang Ding, Haowen Jiang
BACKGROUND: The potential for transurethral resection (TUR) to result in residual tumors in patients with muscle invasive or high-risk non-muscle invasive bladder cancer (NMIBC) may affect local recurrence or progression. This study attempted to evaluate the feasibility and safety of cryoablation as an adjuvant therapy with TUR to treat bladder tumor. METHODS: Patients who met inclusion criteria between December 2014 and August 2015 in our institute was included...
October 2016: Cryobiology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"